Alphatec Holdings Inc (Alphatec), is a medical technology company that designs, develops, manufactures and markets spinal fusion technology solutions and products for the treatment of spinal disorders associated with trauma, disease and degeneration, and congenital deformities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Alphatec’s R&D team is dedicated to meeting the diverse needs of spinal surgery by developing and launching innovative products that enhance its presence in the US spine market. Its focus is on creating technology platforms and products that address major segments of degenerative and deformity spine pathologies. The company’s facilities include a technology advancement cell for rapid prototyping, a cadaveric lab, and a mechanical testing laboratory. As of December 2025, the company owned or held exclusive rights (through its affiliates) to an intellectual property portfolio comprising 178 issued US patents, 51 pending US patent applications, and 268 issued or pending patents in jurisdictions outside the US. In FY2025, the company spent US$76.3 million on its R&D activities, which as a percentage of its revenue stood at 10%.